Kris Cameron Wood

Wood

Assistant Professor of Pharmacology & Cancer Biology

Appointments and Affiliations

  • Assistant Professor of Pharmacology & Cancer Biology
  • Core Faculty in Innovation & Entrepreneurship
  • Member of the Duke Cancer Institute

Contact Information

  • Email Address: kris.wood@duke.edu
  • Websites:

Education

  • Ph.D. Massachusetts Institute of Technology, 2007
  • B.S. University of Kentucky at Lexington, 2002

Research Interests

More effective anticancer therapeutic strategies, many of which are based on functional genomics. Examples of projects include: a miniaturized screening platform, tools to systematically map the signaling pathways controlling anticancer drug responses, high-throughput computational methods to discover anticancer drug combinations, design of therapeutic strategies to reverse or prevent drug resistance, and systematic credentialing of mutations uncovered through cancer genome sequencing projects.

Courses Taught

  • BIOLOGY 728A: University Program in Genetics and Genomics Biological Solutions Module I
  • BIOLOGY 728E: University Program in Genetics and Genomics Biological Solutions Module V
  • CMB 710D: Cell & Molecular Biology Module IV
  • CMB 710E: Cell & Molecular Biology Module V
  • CMB 778A: University Program in Genetics and Genomics Biological Solutions Module I
  • CMB 778E: University Program in Genetics and Genomics Biological Solutions Module V
  • MGM 778A: University Program in Genetics and Genomics Biological Solutions Module I
  • MGM 778E: University Program in Genetics and Genomics Biological Solutions Module V
  • MOLCAN 818: Molecular Mechanisms of Oncogenesis
  • PHARM 393: Research Independent Study
  • PHARM 394: Research Independent Study
  • PHARM 493: Research Independent Study
  • PHARM 494: Research Independent Study
  • PHARM 495: Research Independent Study
  • PHARM 818: Molecular Mechanisms of Oncogenesis
  • UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I
  • UPGEN 778E: University Program in Genetics and Genomics Biological Solutions Module V

In the News

Representative Publications

  • Zhong, Z; Sepramaniam, S; Chew, XH; Wood, K; Lee, MA; Madan, B; Virshup, DM, PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers., Oncogene, vol 38 no. 40 (2019), pp. 6662-6677 [10.1038/s41388-019-0908-1] [abs].
  • Manzari, MT; Anderson, GR; Lin, KH; Soderquist, RS; Çakir, M; Zhang, M; Moore, CE; Skelton, RN; Fèvre, M; Li, X; Bellucci, JJ; Wardell, SE; Costa, SA; Wood, KC; Chilkoti, A, Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models., Science Advances, vol 5 no. 9 (2019) [10.1126/sciadv.aaw9162] [abs].
  • Cakir, M; Mukherjee, S; Wood, KC, Label propagation defines signaling networks associated with recurrently mutated cancer genes., Scientific Reports, vol 9 no. 1 (2019) [10.1038/s41598-019-45603-3] [abs].
  • Lin, KH; Xie, A; Rutter, JC; Ahn, Y-R; Lloyd-Cowden, JM; Nichols, AG; Soderquist, RS; Koves, TR; Muoio, DM; MacIver, NJ; Lamba, JK; Pardee, TS; McCall, CM; Rizzieri, DA; Wood, KC, Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity., Cell Metab, vol 29 no. 5 (2019), pp. 1217-1231.e7 [10.1016/j.cmet.2019.01.011] [abs].
  • Armstrong, AJ; Gupta, S; Healy, P; Kemeny, G; Leith, B; Zalutsky, MR; Spritzer, C; Davies, C; Rothwell, C; Ware, K; Somarelli, JA; Wood, K; Ribar, T; Giannakakou, P; Zhang, J; Gerber, D; Anand, M; Foo, W-C; Halabi, S; Gregory, SG; George, DJ, Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer., Plos One, vol 14 no. 5 (2019) [10.1371/journal.pone.0216934] [abs].